We have developed anew cancer vaccinecandidate based on an MUC1-derivedGalNAc glycopeptide by replacing the threonine residue at the immunodominantepitope with (2S,3R)-3-hydroxynorvaline(Hnv). This evidence concerns the gene MUC1 and cancer.